| Sirtuin 3 expression in the context of Relapsing Remitting Multiple Sclerosis Z Dwyer, N Fudge, C Moore Lithos-The Memorial University Medical Journal 2 (1), 5-12, 2024 | | 2024 |
| Cerebrospinal Fluid and Plasma Immune Cell Phenotyping Combined with Neurofilament Light Chain as Biomarkers of Inflammatory Activity and Disease Modifying Therapy … S Arsenault, C Moore, N Fudge, M Stefanelli, F Clift, L McGrath, ... Neurology 102 (17_supplement_1), 3664, 2024 | | 2024 |
| Transcranial magnetic stimulation enhances the specificity of multiple sclerosis diagnostic criteria: a critical narrative review NJ Snow, HM Murphy, AR Chaves, CS Moore, M Ploughman PeerJ 12, e17155, 2024 | | 2024 |
| Apically localized PANX1 impacts neuroepithelial expansion in human cerebral organoids RJ Noort, H Zhu, RT Flemmer, CS Moore, TJ Belbin, JL Esseltine Cell Death Discovery 10 (1), 1-18, 2024 | | 2024 |
| Radiosynthesis and Characterisation of [18F] antagomir-223: A Potential PET Radiotracer for Imaging Neuroinflammation S Zientek, NK Ramakrishnan, M Alfaidi, WL Kuan, A Fournier, C Moore, ... Nuclear Medicine and Biology 126, 108562, 2023 | | 2023 |
| Bruton Tyrosine Kinase Inhibitors decrease phosphorylation levels and pro-inflammatory cytokine production in healthy controls and relapse-remitting MS patient peripheral blood … R Benoit, N Fudge, C Moore MULTIPLE SCLEROSIS JOURNAL 29, 810-811, 2023 | | 2023 |
| Cross-talk between B cells, microglia and macrophages, and implications to central nervous system compartmentalized inflammation and progressive multiple sclerosis H Touil, R Li, L Zuroff, CS Moore, L Healy, F Cignarella, L Piccio, ... EBioMedicine 96, 2023 | 9 | 2023 |
| Epstein Barr Virus and Multiple Sclerosis: Is a Cure Possible? RY Benoit, CS Moore Viral Immunology 36 (7), 435-437, 2023 | | 2023 |
| Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases E Nutma, N Fancy, M Weinert, S Tsartsalis, MC Marzin, RCJ Muirhead, ... Nature communications 14 (1), 5247, 2023 | 47 | 2023 |
| CXCL10 Is Associated with Increased Cerebrospinal Fluid Immune Cell Infiltration and Disease Duration in Multiple Sclerosis SN Blandford, NJ Fudge, CS Moore Biomolecules 13 (8), 1204, 2023 | 2 | 2023 |
| TAAR1 regulates purinergic-induced TNF secretion from peripheral, but not CNS-resident, macrophages DA Barnes, MC Hoener, CS Moore, MD Berry Journal of Neuroimmune Pharmacology 18 (1), 100-111, 2023 | 5 | 2023 |
| Etifoxine inhibits NLRP3 inflammasome activity in human and murine myeloid cells JM Osmond, JB Williams, PM Matthews, DR Owen, CS Moore bioRxiv, 2023.09. 19.558428, 2023 | | 2023 |
| Does the use of the Bruton Tyrosine Kinase inhibitors and the c-kit inhibitor masitinib result in clinically significant outcomes among patients with various forms of multiple … S Arsenault, RY Benoit, F Clift, CS Moore Multiple Sclerosis and Related Disorders 67, 104164, 2022 | 4 | 2022 |
| Immunophenotyping human cerebrospinal fluid: CXCL10 and neurofilament light chain levels correlate with CSF immune cell subsets and provide pathophysiological relevance in … S Blandford, N Fudge, CS Moore MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 766-767, 2022 | | 2022 |
| Investigating Bruton Tyrosine Kinase Inhibition in human and mouse myeloid cells to further elucidate cell-specific and disease relevant mechanisms in multiple sclerosis R Benoit, N Fudge, CS Moore MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 512-512, 2022 | | 2022 |
| Investigating the NLRP3 inflammasome and its regulator miR‐223‐3p in multiple sclerosis and experimental demyelination DA Galloway, SJ Carew, SN Blandford, RY Benoit, NJ Fudge, T Berry, ... Journal of Neurochemistry 163 (2), 94-112, 2022 | 10 | 2022 |
| Phenotyping Cerebrospinal Fluid in Relapsing-Remitting Multiple Sclerosis; CXCL10 identified as an important mediator of immune cell infiltration SN Blandford, N Fudge, CS Moore MULTIPLE SCLEROSIS JOURNAL 28 (1_ SUPPL), 181-182, 2022 | | 2022 |
| Analysis of plasma using flow cytometry reveals increased immune cell-derived extracellular vesicles in untreated relapsing-remitting multiple sclerosis SN Blandford, NJ Fudge, CP Corkum, CS Moore Frontiers in immunology 13, 803921, 2022 | 7 | 2022 |
| Trace amine receptor-1 (TA (1)) expression is decreased in MS patient immune cells and alters localization in pro-inflammatory macrophages D Barnes, M Hoener, C Moore, M Berry BRITISH JOURNAL OF PHARMACOLOGY 178 (24), 4936-4937, 2021 | | 2021 |
| TAAR1 expression in human macrophages and brain tissue: a potential novel facet of MS neuroinflammation DA Barnes, DA Galloway, MC Hoener, MD Berry, CS Moore International Journal of Molecular Sciences 22 (21), 11576, 2021 | 21 | 2021 |
Jack AntelMcGill University在 mcgill.ca 的电子邮件经过验证
